Our Mission
To discover and develop novel immunotherapies for unmet medical needs. Dedicated to advancing innovative technologies to address the key challenges of traditional cancer therapies and deliver improved treatments for patients with cancer.
Pipeline
Pre-Clinical
Phase I
Phase II
Indication
CAR-T
(Expand to Multiple Cancer Types)
Prostate Cancer
Hematological Malignancy
NT-1921
NT-1921, powered by the SMART technology, is an innovative solution to treat prostate cancer.
- Modulate immune activity of tumor micro environment (TME) by activating tumor-infiltrating lymphocytes(TILs) activity and reducing regulatory T cell (Treg) population in TME
- Improve CAR-T cell proliferation and persistence while minimizing potential systemic side effects
- Enhance the effectiveness of killing cancer cells due to cytokine release & accumulation in TME
- Phase I investigator-initiated trials (NCT05656573) for mCRPC (Metastatic castration-resistant prostate cancer) demonstrated high safety and high efficacy (DCR 100% and ORR30 62% with > 30% decline in serum PSA)
- Potential to re-sensitizing the first-line antiandrogen drugs for mCRPC patients, such as Xtandi (enzalutamide), Erleada (apalutamide), Casodex (bicalutamide) etc.
NT-2022
NT-2022, specifically targeting to B-cell malignancies, is an innovative CAR-T therapy for Hematological Malignancy (ALL, CLL & NHL) and autoimmune diseases
- Modulate immune activity of tumor micro-environment (TME)
- Efficiently block tumor & TME immune checkpoint
- Improve therapeutic activity compared to conventional CAR-T by enhancement of CAR-T cell proliferation and persistence
- Unleash the full anti-tumor potential of CAR-T cell
- Reduce risk of systemic toxicity
Technology
Proprietary nSMART CAR-T Technology
Chimeric antigen receptor (CAR) T cell therapy stands as a transformative advancement and has achieved unprecedented success in cancer immunotherapy. However, there are many challenges limiting its application in solid tumors and hematological malignancies, including life-threatening CAR-T cell associated toxicities, limited efficacy against solid tumors, inhibition and resistance in B cell malignancies, antigen escape, limited persistence, poor trafficking and tumor infiltration, and the immunosuppressive microenvironment.
Nova has developed its own proprietary nSMART CAR-T technology to address the challenges of traditional CAR-T therapy. Our platform enables the effective improvement of the killing efficacy of CAR-T cells against tumors, alleviation of adverse effects, and reduction of the risk of relapse by the distinguished characteristics of the followings:
Switchable
- Precise control of CAR-T cell activation
- Minimize TLS(tumor lysis syndrome) & CRS(cytokine release syndrome)
- Overcome tumor heterogeneity
- Leveraging target antigen density
- Combating antigen-loss/mutation
Immune-Modulatory
- Activate and engage TILs(tumor-infiltrating lymphocytes) in-situ
- Reduce systemic immune modulator exposure
ARmored
- Improve CAR-T cell fitness and persistence
- Improve immunological memory
- Prevent immune suppression in TME